Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes: A Randomized, Controlled Trial

Annals of Internal Medicine

Volumn 138, Issue 12, 2003, Pages

  Fritsche, Andreas ^b   Schweitzer, Matthias Axel ^b   Häring, Hans Ulrich ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; INSULIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SAFETY; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; METABOLISM; MIDDLE AGED; RISK FACTOR; WEIGHT GAIN;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MALE; MIDDLE AGED; RISK FACTORS; SULFONYLUREA COMPOUNDS; WEIGHT GAIN;

EID: 0038131919     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-138-12-200306170-00006     Document Type: Article

References (26)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-7. [PMID: 11742409]
2. Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34. [PMID: 9673301]
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53. [PMID: 9742976]
4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12. [PMID: 10938048]
5. Belfiglio M, De Berardis G, Franciosi M, Cavaliere D, Di Nardo B, Greenfield S, et al. The relationship between physicians' self-reported target fasting blood glucose levels and metabolic control in type 2 diabetes. The QuED Study Group-quality of care and outcomes in type 2 diabetes. Diabetes Care. 2001;24:423-9. [PMID: 11289462]
6. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44:1249-58. [PMID: 7589820]
7. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001;24:758-67. [PMID: 11315844]
8. Peters AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med. 1991;115:45-53. [PMID: 1828656]
9. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-6. [PMID: 11815505]
10. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care. 1997;20:292-8. [PMID: 9051375]
11. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327:1426-33. [PMID: 1406860]
12. Kreider M, Gerich J, Wittlin S. Bedtime insulin in non-insulin dependent diabetes mellitus: rationale, safety, efficacy and recommendations. Diabetes Nutr Metab. 1997;10:82-93.
13. Yki-Jarvinen H, Ryysey L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999;130:389-96. [PMID: 10068412]
14. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23:1130-6. [PMID: 10937510]
15. Gillies PS, Figgitt DP, Lamb HM. Insulin glargine. Drugs. 2000;59: 253-60; discussion 261-2. [PMID: 10730548]
16. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999;42:1151-67. [PMID: 10525654]
17. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet. 2001;358:739-46. [PMID: 11551598]
18. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24:631-6. [PMID: 11315821]
19. Holman RR, Turner RC. A practical guide to basal and prandial insulin therapy. Diabet Med. 1985;2:45-53. [PMID: 2951066]
20. Gerich JE. Hypoglycaemia and counterregulation in type 2 diabetes. Lancet. 2000;356:1946-7. [PMID: 11130519]
21. Groop LC, Widen E, Ekstrand A, Saloranta C, Franssila-Kallunki A, Schalin-Jantti C, et al. Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM. Diabetes Care. 1992;15:831-4. [PMID: 1516500]
22. Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ, Menheere PP, Nieuwenhuijzen Kruseman AC. Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care. 1996;19:1326-32. [PMID: 8941458]
23. Seigler DE, Olsson GM, Skyler JS. Morning versus bedtime isophane insulin in type 2 (non-insulin dependent) diabetes mellitus. Diabet Med. 1992;9:826-33. [PMID: 1473323]
24. Niskanen L, Lahti J, Uusimpa M. Morning or bed-time insulin with or without glibenclamide in elderly type 2 diabetic patients unresponsive to oral antidiabetic agents. Diabetes Res Clin Pract. 1992;18:185-90. [PMID: 1289019]
25. de Sonnaville JJ, Snoek FJ, Colly LP, Deville W, Wijkel D, Heine RJ. Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care. 1998;21:919-24. [PMID: 9614608]
26. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care. 1999;22:1125-36. [PMID: 10388978]